Available online 25 August 2018 Cardiovascular disease (CVD) continues to be a leading cause of death worldwide with atherosclerosis being the major underlying pathology. The interplay between lipids and immune cells is believed to be a driving force in the chronic inflammation of the arterial wall during atherogenesis. Atherosclerosis is initiated as lipid particles accumulate and become trapped in vessel walls. The subsequent immune response, involving both adaptive and immune cells, progresses plaque development, which may be exacerbated under dyslipidemic conditions. Broad evidence, especially from animal models, clearly demonstrates the effect of lipids on immune cells from their development in the bone marrow to their phenotypic switching in circulation. Interestingly, recent research has also shown a long-lasting epigenetic signature from lipids on immune cells. Traditionally, cardiovascular therapies have approached atherosclerosis through lipid-lowering medications because, until recently, anti-inflammatory therapies have been largely unsuccessful in clinical trials. However, the recent Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS) provided pivotal support of the inflammatory hypothesis of atherosclerosis in man spurring on anti-inflammatory strategies to treat atherosclerosis. In this review, we describe the interactions between lipids and immune cells along with their specific outcomes as well as discuss their future perspective as potential cardiovascular targets.
Introduction
Accounting for more than one in four deaths worldwide, cardiovascular disease (CVD) presents a major global health concern (Lozano et al., 2012) . The underlying pathology involved in many forms of CVD is atherosclerosis, a slow progressing chronic inflammatory condition that causes lesions in the arterial wall as well as narrowing of the vessel lumen (Weber & Noels, 2011) . Although several factors contribute to higher individual CVD risk, an overwhelming number of clinical studies have indicated dyslipidemia, or abnormal blood lipid levels, as the key modifiable risk factor in decreasing the manifestations of atherosclerosis (Castelli, Garrison, Wilson, & Levy, 1992; Walldius et al., 2001; Yusuf et al., 2004) . Current therapies approach the problem of atherosclerosis through the use of lipid lowering therapeutics such as statins. Novel, clinically-approved treatments, such proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, have also emerged in recent years; however, their approach to reducing atherosclerosis focuses on lipid lowering, similar to statins (Rosenson, Hegele, Fazio, & Cannon, 2018) . Although these therapies, both individually and synergistically, effectively lower CVD-risk, a large residual risk remains which needs to be addressed by additional therapies (Heidenreich et al., 2011; Hoogeveen et al., 2017) .
To overcome this gap, a considerable amount of research has investigated the interplay between dyslipidemia and immune cells, particularly in genetically modified, hyperlipidemic mice models such as apolipoprotein E deficient (Apoe −/− ) or low density lipoprotein receptor deficient (Ldlr −/− ) mice (Getz & Reardon, 2014) . With this in mind, it is important to note that atherogenesis is not identical in mice and humans. In both cases, plasma lipoproteins help drive plaque development; however, the lipid profiles usually differ between the species as well as between experimental models (Getz & Reardon, 2012) . Therefore, dyslipidemia represents an overarching term that may be the result of diet, genetic manipulation in the case of experimental models, or genetic mutation in the case of familial hypercholesterolemias (FH), and each dyslipidemic condition can be characterized by increases in specific lipids including triglycerides, LDL, and high density lipoprotein (HDL). Nevertheless, dyslipidemia in combination with inflammatory responses drive plaque progression. While these processes represent two separate phenomena, their effects on atherosclerosis are not entirely independent. Studies have targeted both innate and adaptive immune cell types and their subsets to elucidate their function in inflammation under normal and hyperlipidemic conditions in hopes of finding novel therapeutic targets. Recent findings, such as the Canakinumab Antiinflammatory Thrombosis Outcomes Study (CANTOS), have provided intriguing support for the search for innovative anti-inflammation therapies (Ridker et al., 2017) . In this review, we will focus on the latest findings on the interactions of lipids and lipoproteins with immune cells as well as their potential as emerging therapeutic targets.
Atherosclerosis
Atherosclerosis ultimately gives rise to CVD through a two-part mechanism: imbalanced lipid metabolism and maladaptive immune responses (Weber & Noels, 2011) . Its pathogenesis is highly dependent on dyslipidemia as lipids accumulate in regions of disturbed blood flow in the vessel's intimal layer, which leads to innate immune cell (see Appendix A) recruitment and activation. Cellular adhesion molecules, which have be shown to be upregulated by lipoproteins including LDL, mediate the process of leukocyte attachment and diapedesis (Gebuhrer, Murphy, Bordet, Reck, & McGregor, 1995) . Selectins and their ligands, such as P-selectin and P-selectin ligand, form a weak tether between immune cells and endothelial cells within the vessel. Additional molecules such as intercellular adhesion molecules (ICAMs) and vascular cell adhesion molecules (VCAMs) induce firm adhesion, which allows immune cells to migrate towards the deposited lipids within the intimal layer (Blankenberg, Barbaux, & Tiret, 2003) . Monocytes invade early lesions to mediate lipoprotein internalization and cytokine production eventually differentiating into archetypal foam cells. In turn, adaptive immune cells such as T and B lymphocytes (see Appendix A) are attracted to the lesion site leading to a concentrated site of localized inflammation and chemokine secretion. The continuous influx of innate and adaptive immune cells, in combination with the ineffective macrophage efferocytosis of apoptotic and necrotic cells, advances necrotic core formation within plaques in the vessel wall (Doran et al., 2017; Getz & Reardon, 2014; Tse, Tse, Sidney, Sette, & Ley, 2013) . Cholesterol accumulating in atherosclerotic lesions has been previously found to undergo modifications (see Glossary) such as oxidization, which exacerbates inflammatory responses. As the lesion advances, it may become destabilized with excessive amounts of lipids and immune cells (Hoogeveen et al., 2017) . These vulnerable plaques have the potential to rupture leading to clinical symptoms such as thrombosis, myocardial infarction, or cerebral infarction. To better understand the mechanisms underlying the clinical manifestations of atherosclerosis, more research needs to be applied to the current knowledge we have surrounding the interactions of lipids and our immune system.
Dyslipidemia and immune cells

Lipids and hematopoietic stem and progenitor cells
As outlined above, the combination of abnormal lipids and activated immune cells clearly contributes to atherogenesis. However, the mechanism maintaining the chronic state of inflammation seen in the arterial wall during atherosclerosis remains unclear. Although the effects of atherosclerosis are primarily seen in the arteries and immune cells of the circulatory system, as well as in lymphoid organs, recent studies have suggested a systemic pro-inflammatory phenotype originating in hematopoietic stem and progenitor cells (HSPCs)(see Glossary) which may direct the inflammatory state in immune cells and atherosclerotic plaques (Hoogeveen et al., 2017) . These HSPCs are responsible for the renewal and eventual differentiation of the myeloid, lymphoid, and erythroid cell lineages. Although HSPCs maintain our immune cell populations, major knowledge gaps exist, particularly for lymphoid and erythroid progenitors, during their interactions with lipids in the context of atherosclerosis. Therefore, we will only discuss interactions between dyslipidemia and myeloid progenitors in detail.
Increases in bone marrow mobilization
Typically their differentiation is a tightly controlled process responding to the bone marrow niche to replenish or expand immune effector cells; however, HSPCs have also been shown to respond to environmental stimuli in cases like dyslipidemia. For example, in both Apoe −/− and Ldlr −/− mice, studies have shown that hyperlipidemia activates HSPCs causing an increase in their proliferation and total number. In humans, bone marrow hyper-responsiveness, including increased cluster of differentiation-34+ (CD34+) progenitor populations, has been associated with both preclinical risk factors like increased serum LDL concentrations as well as after clinical events like acute myocardial infarctions (Assmus et al., 2012; Cimato, Palka, Lang, & Young, 2013; Van Der Valk et al., 2017) . As shown in Fig. 1 , these increases in HSPCs have been associated with a circulating leukocytosis and, in particular, monocytosis and neutrophilia, which themselves are associated risk factors for cardiovascular disease (Coller, 2005; Dutta et al., 2013; Giugliano et al., 2010; Murphy et al., 2011; Seijkens et al., 2014) . In ischemic tissue, estimates have shown the residence time for innate immune cells to be roughly 19 h necessitating the need for the observed increased bone marrow mobilization and proliferation to account for their high turnover rate (Leuschner et al., 2012) . Interestingly, this primed monocytic/granulocytotic phenotype has been reproduced in bone marrow chimeras of hyperlipidemic mice models transplanted with normal HSPCs and vice versa suggesting the effect is either on the bone marrow niche or the HSPC itself (Murphy et al., 2011; Seijkens et al., 2014) . On one hand, disruptions in the CXCL12/CXCR4 axis (see Appendix A), a key regulator of HSPC mobilization, in the bone marrow niche have been suggested as the mechanism behind this phenomenon. In addition to the CXCL12/CXCR4 pathway, studies also indicated an appreciable regulatory role for cholesterol efflux pathways via ATP binding cassette A1 (ABCA1), ABCG1, and HDL in HSPC mobilization from the bone marrow. ABCA1
−/− and ABCG1 −/− mice, with defects in cholesterol efflux pathways, showed imbalanced cholesterol homeostasis, increased extramedullary hematopoiesis, and dysregulated expression of cytokines including interleukin (IL)-23/IL-17/ granulocyte-macrophage colony-stimulating factor (GM-CSF), which modified the bone marrow niche by decreasing CXCL12-producing cells allowing for HSPC mobilization (Gomes et al., 2011; Westerterp et al., 2012; Yvan-Charvet et al., 2010) . Remarkably, hyperlipidemic Apoe −/− mice injected with neutralizing antibodies targeting IL-3 and granulocyte-CSF (G-CSF) showed a reduction in HSPC mobilization and a concomitant decrease in circulating myeloid populations (Robbins et al., 2012) .
Lipid-driven reprogramming of HSPCs
Interest has been growing in the reprogramming of the myeloid progenitors within the bone marrow through epigenetic modifications allowing for long-term memory of innate cells termed 'trained immunity.' Early trained immunity studies induced memory in innate immune cells through the use of β-glucan, which after secondary challenges with LPS resulted in a primed expansion of progenitors of the myeloid lineage as well as increased signaling of immune mediators IL-1ß and GM-CSF. More recently, in the cardiovascular domain, trained immunity was induced in Ldlr −/− mice via a high-fat diet (HFD) resulting in a similar pro-inflammatory phenotype with increased myeloid progenitors mediated through the Nod-like receptor protein 3 (NLRP3) inflammasome (Christ et al., 2018; Mitroulis et al., 2018) . Both mechanisms, either via modifications of the bone marrow niche or effects on the HSPCs themselves represent potential therapeutic targets, which we will discuss in more detail below.
Lipids and innate immune cells
Similar to the immune response during other inflammatory disorders, innate immune cells are the first responders in the case of dyslipidemia. As described, hyperlipidemia induces increased numbers of both circulating neutrophils and monocytes in experimental mice models and patients, which can be attributed to increased HSPC proliferation and mobilization (Giugliano et al., 2010; Seijkens et al., 2014) . In the cardiovascular domain, increases in both cell populations have been shown to correlate to plaque burden (Drechsler, Megens, Zandvoort, Weber, & Soehnlein, 2010; Imanishi et al., 2010; Ionita et al., 2010; Swirski et al., 2007) . While there is Fig. 1 . Interactions between lipids, such as LDL or oxLDL, and HSPCs as well as innate immune cells. Lipids may induce changes directly on HSPCs through epigenetic changes, and they also have been associated with disruptions in the bone marrow niche allowing for increased proliferation and mobilization. The epigenetic signature of HSPCs can be altered by lipid-driven upregulation or downregulation of various epigenetic enzymes including histone methylases and demethylases. These changes can be carried from stem cells to differentiated cells in circulation and tissue. Alternatively, lipids have also been associated with disputing key recruitment and homing pathways like the CXCL12/CXCR4 pathway in the bone marrow niche. Changes induced by these disruptions can be seen in increases in extramedullary hematopoiesis in the spleen as well as increased proliferation of CD34+ progenitor cells. Both changes eventually lead to a circulating neutrophilia and monocytosis with increase signaling of the NLRP3 inflammasome.
accumulating evidence for the role of neutrophils in atherosclerosis, studies involving the specific effects of hyperlipidemia on mature neutrophils are lacking. However, the interactions between monocytes and lipids in atherosclerosis have been well-studied over the past decades.
Increases in circulating monocytes
In circulation, monocytes are typically divided into classical inflammatory monocytes or non-classical patrolling monocytes. Murine monocyte subsets are generally recognized depending on their expression of Ly6C, with higher expression in inflammatory monocytes. Human subsets, on the other hand, can be divided as CD14
++
CD16
− classical monocytes and CD14 dim CD16 + non-classical monocytes (Boyette et al., 2017; Ingersoll, Platt, Potteaux, & Randolph, 2011) . Although some differences exist between the human and mice subsets, they are generally considered to be orthologous based on experimental data such as gene expression analysis (Ingersoll et al., 2010) . Interestingly, recent studies have indicated lipoproteins may activate circulating monocytes in plasma (Bernelot Moens et al., 2017) . In both humans and mice models, hypercholesterolemia leads to a specific increase in inflammatory monocyte populations, which are thought to be highly infiltrative especially in the case of atherosclerosis (Seijkens et al., 2014; Tolani et al., 2014) . Repeatedly, research has shown these elevated concentrations of murine Ly6C high inflammatory population more readily invade atherosclerotic lesions (Ortega-Gómez, Perretti, & Soehnlein, 2013; Swirski et al., 2007; Tacke et al., 2007) . Clinical studies have even suggested using circulating levels of inflammatory CD14 ++ CD16 − monocytes as an independent predictor of cardiovascular events in humans making them a putative target for therapeutic agents (Berg et al., 2012; Weber et al., 2011) . While lipid concentrations highly affect monocytes, the effect of dyslipidemia on differentiated macrophages provides the basis for the traditional sequelae observed in atherosclerosis.
Activation of macrophages and foam cell formation
Lipid retention in the vessel wall acts as a key inflammatory trigger in atherosclerosis by activating pattern recognition receptors such as Toll-like receptors (TLRs) on macrophages that have infiltrated the vessel's intimal layer (Cole, Kassiteridi, & Monaco, 2013; Westerterp et al., 2014) . These retained lipoproteins may undergo modifications such as oxidization and can thereby act as damage-associated molecular patterns (DAMPs) to stimulate TLRs or they can be engulfed by macrophages (Binder, Papac-Milicevic, & Witztum, 2016) . TLR stimulation initiates a large immune response through the expression of several pro-inflammatory and anti-inflammatory cytokines ultimately attracting additional innate and adaptive immune cells to the plaque (Schaftenaar, Frodermann, Kuiper, & Lutgens, 2016) . Lipid uptake and accumulation in macrophages can also coincide with the occurrence of cholesterol crystals, which can further activate these cells through the NLRP3 inflammasome, leading to the secretion and cleavage of IL-1 cytokines (Duewell et al., 2010) .
When the balance between influx and efflux of cholesterol is disturbed, cholesterol will accumulate in the macrophages and they will take on the appearance of foam cells. Notably, cholesterol homeostasis within immune cells like macrophages may be controlled through internal cholesterol biosynthesis pathways through the regulation of the transcription factor sterol regulatory element-binding protein 2 (SREBP2) or efflux mechanisms involving liver X receptors (LXR). While investigating the effect of hyperlipidemia on peritoneal foam cell formation in Ldlr −/− mice, Spann et al. demonstrated that a HFD was associated with a deactivated rather than an inflammatory phenotype. The researchers attributed this phenotype to the accumulation of desmosterol, the final intermediate within the cholesterol synthesis pathway, within foam cells, which has been associated with regulation of both cholesterol homeostasis pathways through suppression of SREBP2-coordinated biosynthesis as well as activation of LXRs (Spann et al., 2012; Yang et al., 2006) . Desmosterol, unlike other LXR agonists, is decoupled from pathways that upregulate fatty acid biosynthesis that ultimately lead to hypertriglyceridemia. Therefore, desmosterol and other sterol-based regulators have been gaining attention as potential atherosclerosis therapeutics based on their reciprocal activities on cholesterol homeostasis pathways (Muse et al., 2018; Spann et al., 2012) .
Lipid-driven reprogramming of innate immune cells
Although hyperlipidemia can account for the initial increase and infiltration of inflammatory monocytes and macrophages in atherosclerosis, the mechanisms behind the sustained pro-inflammatory state of these short-lived innate immune cells remains unresolved (Hoogeveen et al., 2017) . To this end, a shift in the classical immunological paradigm has challenged the dichotomy of innate versus adaptive immunity where innate immune cells, like monocytes and macrophages, may develop memory-like features through epigenetic and metabolic reprogramming (Ifrim et al., 2014; Netea, Quintin, & Van Der Meer, 2011) . In the context of atherosclerosis, several pro-atherogenic stimuli, such as oxidized LDL (oxLDL) and lipoprotein(a), have been shown to induce a primed pro-inflammatory state in innate immune cells. After in vitro incubation with oxLDL, human monocytes were found to exhibit a pro-atherogenic phenotype characterized by increased pro-inflammatory cytokine expression as well as increased trimethylation of lysine 4 at histone 3 (H3K4me3). In line with this, recent research demonstrated that a myeloid deficiency of the histone demethylase Jumonji domaincontaining protein 3 (Jmjd3, or also known as Kmd6b), which counteracts increases in histone methylation similar to H3K4me3, resulted in more advanced atherosclerosis in hyperlipidemic mice (Neele et al., 2018) . Furthermore, ex vivo studies of monocytes isolated from patients with elevated levels of lipoprotein(a) exhibited a trained immune phenotype consisting of increased cytokine production, cell adhesion, and migration. In this case, both metabolic reprogramming through upregulation of glycolytic enzymes and epigenetic reprogramming through increased histone methylation were identified (Van Der Valk et al., 2016) . In studies outside the realm of atherosclerosis, trained or primed monocytes were able to respond to secondary stimuli in a hyper-responsive manner for up to three months (Kleinnijenhuis et al., 2012) . Epigenetic modifications have gained increased attention and, in some fields like cancer, even FDA approval for treatment (Hoogeveen et al., 2017) . Combined with our expanding knowledge of lipid-immune cell interactions, mechanisms behind epigenetic and metabolic reprogramming represent a wide field of research for potential therapeutics.
Inhibitory effects on dendritic cells
Of note, macrophages link innate and adaptive immune responses in atherosclerosis by attracting lymphocytes to the site of inflammation after expression of a myriad of cytokines (Schaftenaar et al., 2016) . However, other innate immune cells such as dendritic cells (DC) play key roles in activating adaptive immune cells as well. The traditional immunological paradigm describes DCs patrolling tissue and upon activation migrating to lymph nodes to present antigens in order to activate T cells (Gil-Pulido & Zernecke, 2017) . Surprisingly, in the context of atherosclerosis, hyperlipidemia has been shown to impair the migration of these antigen-presenting cells (APCs) after oxLDL induced upregulation of inhibitory signals (Angeli et al., 2004) . In line with these results, a reduction in APCmediated pathogen clearance from plaques has also been described in hyperlipidemic mice, further corroborating inhibitory effects of lipids on DCs (Roufaiel et al., 2016) . While in the plaque, resident DCs exhibit enhanced lipoprotein uptake, which may adopt a foamcell appearance similar to macrophages (Gil-Pulido & Zernecke, 2017) . Given that a reduced emigration capacity of DCs has been associated with dyslipidemia, antigen presentation by these cells may still occur in lymphoid organs, but it may also occur locally within arteries. Several studies have shown that murine aortic DCs are able to activate T cells increasing both their proliferation and expression of pro-inflammatory cytokines, which may be a driving force in the chronic inflammation seen during atherosclerosis (Choi et al., 2011; Koltsova et al., 2012; Weber et al., 2011) . Further research into the communication and interactions between lipidimmobilized, lesional DCs and T cells may shed light on promising new therapeutic targets.
Lipids and adaptive immune cells
Parallel to the innate immune system, the interplay between hyperlipidemia and adaptive immune responses play a key role in atherogenesis. As touched upon, presentation of antigens such as modified LDL or its components triggers adaptive immune responses, which can be seen with the presence of both activated T cells and antibody-producing B cells associated with atherosclerotic plaques (Grivel et al., 2011; Hu et al., 2015) . The interaction between lipids and adaptive immune cells as well as the co-stimulatory and co-inhibitory pathways associated with these cell types has been a major focus of cardiovascular research in recent years.
Lipid metabolism and cell proliferation
After interaction with APCs, T cells become activated and subsequently proliferate to expand in response to antigen exposure as shown in Fig. 2 . Surprisingly, cholesterol metabolism also plays a major role in the proliferative abilities of these cells. Proliferation requires large amounts of lipids for membrane synthesis, which they can satisfy either through endogenous synthesis or exogenous uptake via the LDL receptor (Bietz, Zhu, Xue, & Xu, 2017) . In case of imbalanced cholesterol homeostasis, cells upregulate LXRs to promote cholesterol efflux or they internalize the LDL receptor for degradation (Bagley, Yuan, & Iacomini, 2017) . However, when cells interact with modified lipoproteins like oxLDL, these protective mechanisms may be impaired. For example, oxLDL has been shown to direct differentiation to T effector (Teff) cells, which promote inflammation, while cholesterol efflux mechanisms involving LXRs and HDL favor differentiation towards the immunosuppressive T regulatory (Treg) population (Herold et al., 2017; Maganto-García, Tarrio, Grabie, Bu, & Lichtman, 2011; Newton & Benedict, 2014) .
T regulatory and effector cell effects
Typically, functional phenotype switching in T cells allows the immune system to react to environmental stimuli, including atherogenic stimuli like oxLDL, by modifying the ratio of effector to regulatory cells (Su, del Alcazar, Stelekati, Wherry, & Davis, 2016; Tabas & Lichtman, 2017) . In hyperlipidemic Ldlr −/− mice, a decrease in the lesional Treg but not Teff cell populations was observed during plaque development (Maganto-García et al., 2011) . Mechanistically, in vitro studies of the effect of oxLDL on Tregs showed a reduction in the key lineage-determining transcription factor forkhead box P3 (foxp3), and in their immunosuppressive abilities. Adoptive transfer studies applying Tregs established their atheroprotective role through reductions in aortic sinus plaques (Mor et al., 2007) . One study suggested that the role of Tregs in modulating lipoprotein metabolism was the key to their atheroprotective nature, as Treg-deficient mice exhibited a 1.7-fold increase in plasma cholesterol that highly favored VLDL accumulation as a result of reduced expression of sortilin-1 (Klingenberg et al., 2013) . Accordingly, IL-10, an anti-inflammatory cytokine associated with Tregs, has been shown to reduce both serum VLDL and LDL levels in Ldlr in circulation as well as in lymphoid organs and the aorta. Furthermore, bone marrow of Apoe −/-CD27 −/− mice reconstituted with Apoe −/-CD27 +/+ Tregs exhibited reductions in lesion sizes (Winkels et al., 2017) . Considering that low levels of circulating Tregs are associated with increased CVD risk, increasing either the number or function of Treg populations in patients remains a very attractive therapeutic approach (Mor, Luboshits, Planer, Keren, & George, 2006) . Modulating the pro-inflammatory effects of Teff cells during atherosclerosis, on the other hand, is an equally relevant therapeutic target. Lipid-driven cell recruitment to plaques initiates a myriad of cytokines ultimately leading to the expression of co-stimulatory molecules such as CD40 on APCs (Tuñ et al., 2018) . Although still somewhat controversial, antigenic stimulation of T cells through APCs in the context of atherosclerosis has been shown to be primarily associated with lipid antigens like oxLDL as well as heat shock proteins in both humans and mice (Afek et al., 2000; Kervinen et al., 2003; Zhu et al., 2001) . Afterwards, various co-stimulatory dyads can activate T cells to differentiate into Th1 (T helper), Th2, or Th17 effector cell populations. Th1 cells dominate the T cell response in plaques while promoting vascular inflammation through secretion of Interferon-γ (IFN-γ) (Laurat et al., 2001; Mallat, Taleb, Ait-Oufella, & Tedgui, 2009) . To this end, injection of IFN-γ in Apoe −/− mice was shown to reduce serum cholesterol concentrations, but actually increase atherosclerotic lesion sizes marking it a pro-atherogenic cytokine (Whitman, Ravisankar, Elam, & Daugherty, 2000) . Conversely, in Apoe
mice, a Th1 lineage-determining transcription factor knockout mice model, the Th1 response was downregulated and resulted in reduced plaque formation (Buono et al., 2005) .
To further complicate the role of T helper cell subsets in atherosclerosis, the function of Th2 and Th17 cells in atherosclerosis are still under investigation. IL-4 is a prototypical Th2 cytokine, which has been shown to counteract the production of IFN-γ (Tse et al., 2013) . It would appear that Th2 cells are athero-protective, but murine studies have indicated that IL-4 production may upregulate several atherogenic molecules including VCAM-1 and monocyte chemoattractant protein 1 (MCP-1) that are associated with plaque progression (Lee, Kühn, Hennig, Neish, & Toborek, 2001; Walch, Massade, Dufilho, Brunet, & Rendu, 2006) . Studies involving Th17 and its prototypical cytokine IL-17 have reported inconsistent results as well. Taking into account that IL-17 activates proinflammatory pathways leading to upregulation of IL-1ß and tumor necrosis factor-α (TNF-α), Th17 cells may be viewed as an atherogenic population. Ldlr −/-IL-17A −/− knockout mice models have repeatedly shown reductions in atherosclerosis; however, treatment with mouse anti-IL-17a antibodies found no significant reductions, ultimately blurring the role of these cells in disease development (Butcher, Gjurich, Phillips, & Galkina, 2012; Cheng et al., 2011; Taleb, Tedgui, & Mallat, 2015) .
Lipid-driven reprogramming of adaptive immune cells
It becomes abundantly clear that T cells play a major role in atherosclerosis, but the mechanisms driving the plasticity among T helper and regulatory populations have remained largely unchallenged in recent years. The traditional immunological paradigm ascribes certain lineage-defining transcription factors and cytokines to each subset, such as foxp3 and TGF-β for Tregs (Tse et al., 2013) . While this paradigm remains true, recent studies have begun investigating the effect of environmental stimuli on epigenetic landscape of T cells during their activation and eventual differentiation. DNA methylation plays an important role during differentiation as naïve T cells undergo an epigenetic shift that allows for transcription factors to bind to the necessary loci. The relevance of DNA methylation in T-cell differentiation has been shown in other chronic inflammatory conditions such as systemic lupus erythematosus where disease flares were associated with changes in helper and regulatory cell populations induced both via hypo-and hypermethylation. In particular, Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, has been implicated in studies involving transcriptional silencing of T helper cell populations (Coit et al., 2016) . Similar to the primed monocyte phenotype described above, EZH2 is associated with methylation at H3K4me3 making it an interesting therapeutic target in both innate and adaptive immune cells (Hoeksema & de Winther, 2016; Koyanagi et al., 2005; Tong et al., 2014) . However, more studies need to investigate the effect of lipids and their modified counterparts, like oxLDL, on epigenetic reprogramming in T cells.
B cells and their subtypes
Finally, a limited effect of hyperlipidemia can also be observed when interrogating B cells. Initial studies indicated that B cells are atheroprotective, as increases in atherosclerotic lesions were found in B cell-deficient mice, achieved either through splenectomy or bone marrow transplant from B cell-deficient mice into lethally irradiated Ldlr −/− mice (Caligiuri, Nicoletti, Poirierand, & Hansson, 2002; Major, Fazio, & Linton, 2002) . Antibodies directed against modified lipoproteins, like oxLDL, were proposed as their protective mechanism (Lewis et al., 2009) . While this mechanism was confirmed for some subsets of B cells, the differing roles of B1 and B2 cells in atherosclerosis has remained controversial. B1 cells are a subset of B cells belonging to the innate immune system that generate T cell-independent natural IgM antibody responses while B2 cells mount antibody responses in a T cell dependent manner, particularly using with the co-stimulatory OX40-OX40L pathway (Schaftenaar et al., 2016) . IgM oxLDL antibodies generated by B1 cells, including B1a and B1b subsets, are associated with protection against atherosclerosis by reducing the oxLDL uptake by macrophages (Ishigami et al., 2013; Rosenfeld et al., 2015) . On the other hand, IgG oxLDL antibodies generated by B2 cells have been reported as pro-atherogenic, which might be explained by IgG immune complexes depositing in the plaque (Tsiantoulas, Diehl, Witztum, & Binder, 2014) . In view of these results, the application of targeted oxLDL antibodies may warrant more in-depth research, before becoming a feasible therapy for atherosclerosis. However, the latest data from Que. et al. show that targeting oxidized phospholipids (OxPL) by a single-chain fragment of the IgM natural antibody E06 successfully inhibits the macrophage uptake of OxLDL and prevents OxPL-induced inflammatory signaling. This data suggest that therapies inactivating OxPL may be beneficial to inhibit inflammation and thereby the progression of atherosclerosis (Que et al., 2018) .
Therapeutics
Lipid-lowering therapies
Statins and PCSK9 inhibitors
Currently, cardiovascular therapies mainly focus on lowering serum lipid levels through the use of statins; however, other lipidlowering therapies have been developed recently which have shown moderate successes in reducing CVD risk as well. Statins target hepatocytes to effectively obstruct cholesterol synthesis by inhibiting the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. Hepatocytes upregulate expression of cell surface LDL receptors to compensate for the statin-induced reduction in endogenous cholesterol, which successfully lowers serum lipid levels (Stancu & Sima, 2001 ). In practice, statin therapy aims to reduce non-HDL cholesterol significantly to reduce CVD risk. However, clinical practice has shown that statin therapy alone may not be sufficient to reduce individual risk as factors such as genetic predisposition in familial hypercholesterolemia (FH), drug intolerance, or non-adherence of statin therapy play important roles (Chaplin, 2017) . Therefore, additional lipid-lowering therapies have recently been developed to further reduce cholesterol levels.
(PCSK9 inhibitors, in particular, have yielded up to 50-60% reductions in LDL when taken in combination with statins in patients suffering from FH (Blom et al., 2014) . This therapy focuses on inhibiting PCSK9, which under normal conditions would signal for the degradation of the LDL receptor on hepatocytes. Similar to statins, increased availability of the LDL receptor during treatment leads to lower serum lipid levels (Page & Watts, 2018) .
Reconstituted HDL
In addition to these FDA-approved therapies, experimental therapies using reconstituted HDL (rHDL) to lower lipids have been proposed from murine studies. We described earlier how the bone marrow niche may respond to hypercholesterolemia with increased mobilization and proliferation leading to a clinical monocytosis in patients. Studies have described the mechanism as defective cholesterol efflux, which in part could be attributed to reduced HDL levels. To test this hypothesis, researchers substantially lowered murine HDL concentration using a LDLr (Tolani et al., 2014) . In rheumatoid arthritis, a chronic inflammatory disease with similarities to atherosclerosis, mouse models have shown increased HSPC proliferation with monocytosis and neutrophilia as well. Although enhanced inflammatory monocyte populations that preferentially infiltrated atherosclerotic plaques were observed, this phenotype could be reversed with the administration of rHDL (Dragoljevic et al., 2018) . Unfortunately, most clinical studies targeting HDL failed to improve CV outcome. However, differences in HDL subclasses may explain failures of previous clinical studies (Woudberg et al., 2018) . Further exacerbating this problem, recent research has demonstrated a pro-inflammatory effect of HDL on macrophages contradicting its long held anti-inflammatory role (Van Der Vorst et al., 2017) . Targeting cellular cholesterol efflux mechanisms via subclasses of HDL remains a therapeutic target with great potential; however, additional research is needed to elucidate and expand our knowledge of the role of HDL in humans.
Anti-inflammation benefits
There is also increasing evidence that lipid-lowering therapies have anti-inflammatory and immunomodulatory benefits as well. Statins have been shown to decrease the activity of NF-kB, which is a key transcription factor associated with inflammation induced through the NLRP3 inflammasome during atherosclerosis (Duewell et al., 2010; Hölschermann et al., 2006) . Importantly, this reduction in activity has also been accompanied by decreased production of inflammatory cytokines such as IL-6 and IL-8 (Iwata et al., 2012) . In line with this, statins have also been associated with a decrease in inflammatory biomarkers, namely C-reactive protein (CRP), but there may be great inter-individual variation between patients (Ridker et al., 2005) . While lacking reductions in serum CRP, PCSK9 inhibitor therapy has nevertheless revealed other anti-inflammatory side effects (Baruch et al., 2017) . In FH patients, PCSK9 monoclonal antibodies successfully reduced lipoprotein(a) as wells as pro-inflammatory cytokine, TNF-α, production while increasing anti-inflammatory cytokine, IL-10, production. Changes in both macrophage phenotype and migration were also associated with PCSK9 therapy (Bernelot Moens et al., 2017) . Anti-inflammatory benefits from experimental therapies, like rHDL, remain to be demonstrated in human trials.
Unfortunately, these lipid-lowering therapies, particularly statins, leave a large residual risk of cardiovascular complications (Heidenreich et al., 2011; Hoogeveen et al., 2017) . Throughout this paper, we have discussed the interplay between lipids and immune cells, which synergistically drive plaque progression in atherosclerosis. Mechanistically, this idea is not new and many clinical trials, as shown in Table 1 , have also tested the association of anti-inflammatory treatments with CVD risk. Until recently, though, many large clinical studies could provide no beneficial evidence for the widespread implantation of non-steroidal anti-inflammatory therapies to reduce CVD risk (Antman et al., 2007; McGettigan & Henry, 2011) . However, the recent CANTOS trial provided intriguing support for the inflammatory hypothesis of atherosclerosis. As the first proof-of-principle cardiovascular intervention trial specifically targeting inflammation in humans, patients with previous myocardial infarction and a high-sensitivity CRP level N 2 mg/L treated with monoclonal antibodies against IL-1ß, a master cytokine of innate immunity, witnessed a reduction in both circulating pro-inflammatory biomarkers and incidence rates for cardiovascular events (Ridker et al., 2017) . Through this, the search for therapeutics within inflammatory processes has been validated in the context of atherosclerosis.
Anti-inflammation and immune modulating therapies
As we discussed in earlier sections, the combination of innate and adaptive immune cell responses plays a critical role in the progression of atherosclerosis in response to dyslipidemia. In light of the CANTOS trial, these two separate branches of immunity present great potential for a variety of options of different targeted therapeutics to prevent plaque development. In order to direct therapeutics against specific immune responses, researchers have targeted particular cytokines, cell markers, and cell populations in both experimental mice models and ongoing clinical trials.
Cytokine directed therapies
Currently, the most prominent and anticipated clinical studies involving potential anti-inflammatory cardiovascular therapeutics revolve around innate immune cell secreted cytokines. As we described previously, lipid-driven activation of the NLRP3 inflammasome can influence the maturation and expression of IL-1ß, which itself has been shown to induce IL-6 expression (Duewell et al., 2010; Tosato & Jones, 1990) . While the nature of IL-6 remains somewhat controversial, both cytokines have been linked with inflammation during atherosclerosis in animal models. Knockout models involving IL-1RN, an inhibitor of IL-1 and its downstream cytokines such as IL-1ß, resulted in severe inflammation with increased macrophage populations in inflammatory lesions in the adventitia under hyperlipidemic conditions (MerhiSoussi et al., 2005) . Furthermore, targeted treatment with monoclonal antibodies against IL-1ß in Apoe −/− mice showed a significant reduction in plaque formation (Bhaskar et al., 2011) . Similarly, IL-6 has been shown to be highly expressed in atherosclerotic plaques, and elevated plasma levels of the cytokine are associated with increased cardiovascular risk (Nus & Mallat, 2016; Reiss, Siegart, & De Leon, 2017) . Therefore, both IL-1ß and IL-6 are targets of two separate, randomized placebocontrolled clinical trials. We have already discussed the success of CANTOS targeting IL-1ß in the previous section, and we expect to see the results of Cardiovascular Inflammation Reduction Trial (CIRT) by the end of 2018. Unlike CANTOS, the CIRT study administers a lowdose of methotrexate (15-20 mg/week) to inhibit the pro-inflammatory effects of IL-6. Methotrexate is routinely used to treat other chronic inflammatory disorders such as rheumatoid arthritis; therefore, its transition to a cardiovascular application appears warranted (Everett et al., 2013; Yamashita, Sasaki, Kasahara, & Hirata, 2015) . Furthermore, the Colchicine Cardiovascular Outcomes Trial (COLCOT) also plans to evaluate whether long-term treatment with colchicine, an anti-inflammatory drug already approved for acute use in patients with gout, may reduce CV events. If successful, both clinical trials would further support evidence for the inflammatory hypothesis of atherosclerosis alongside the results of the CANTOS trial.
Small molecular inhibitors
In addition to cytokines, researchers have begun to direct targeted therapeutics to specific immune cell populations using cell markers.
Co-stimulatory dyads such as CD40-CD40L signaling between DCs or monocytes and T cells have long been established as pro-inflammatory pathways (Elgueta et al., 2009; Schönbeck, Sukhova, Shimizu, Mach, & Libby, 2000) . Unsurprisingly though, long-term blockade of these pathways leads to severe immune deficiencies as their roles are quite complex between cell types, which makes therapeutic development challenging. However, recent approaches using small molecule inhibitors to specifically block downstream targets of these co-stimulatory dyads have been very promising. For example, Seijkens et al. developed a small molecule inhibitor termed TRAF-STOP intended to disrupt the pro-inflammatory CD40-tumor necrosis factor receptor-associated factor (TRAF) 6 signaling pathway during atherosclerosis. Although the TRAF-STOPs were most efficient in blocking inflammation in the myeloid lineage, when given as bare compound, researchers also used rHDL nanoparticles to carry these TRAF-STOPs directly to macrophages for uptake. After engulfment, the TRAF-STOPs effectively abolished CD40-TRAF6 signaling. Significant reductions in the progression of both early and established atherosclerosis, leukocyte recruitment, and macrophage activation were accomplished, and, favorably, classical CD40 signaling such as DC-mediated T-cell activation was unimpaired thereby circumventing immune suppressive side effects (Lameijer et al., 2018; Seijkens et al., 2018) . A cell specific approach using targeted therapeutics directed against cell markers without complete signaling ablation is an innovative strategy that has great potential considering the wide variety of immune cell phenotypes seen throughout the progression of atherosclerosis. Blockade of other cell markers such CD47, which inhibits cell efferocytosis within plaques, or Triggering Receptor Expressed on Myeloid cells-1 (TREM-1), which amplifies the innate immune response, through the use of similar therapeutic agents could be promising targets as well (Barclay & van den Berg, 2014; Y. S. Wang, Li, & Zhao, 2012) . Potentially, specific immune cell responses could be better controlled through similar therapeutics allowing physicians to regulate cytokine production and immune cell interactions that drive atherogenesis, like some macrophage and Teff cell populations.
Immunomodulation therapies
Interestingly, research into augmenting atheroprotective cell populations like Tregs has shown moderate successes as a potential therapeutic as well. As we described previously, Tregs play a key role in suppressing excessive immune responses especially in inhibiting the progression of atherosclerosis. In fact, a recent clinical study showed a decrease in Treg population in comparison to Teff cell population in coronary artery disease (Emoto et al., 2014) . In order to expand Treg populations in vivo, induction with IL-2, a key cytokine for the differentiation and proliferation of Tregs, has been suggested as a potential therapy. Using hyperlipidemic Apoe −/− mice, researchers were able to show both a reduction in atherosclerosis and an expansion of the CD4 + CD25 + Foxp3+ Treg population using a IL-2/anti-IL-2 monoclonal antibody complex (Dinh, Kyaw, Kanellakis, Tipping, et al., 2012) . Interestingly, another study using a similar IL-2/anti-IL-2 complex in addition to anti-CD3 vaccine also showed remarkable reductions in atherosclerosis in Apoe −/− mice, which they attributed to an improved Treg to Teff cell ratio (Kasahara et al., 2014) . Augmentation of the Treg population has been shown to be possible though adoptive transfer studies in mice, which also lead to reduced atherosclerosis (Ait-Oufella et al., 2006) . Clinical trials have begun testing the effect of ex vivo expanded autologous Treg transplantations on several disease states, but human data is still lacking for atherosclerosis (Bullenkamp, Dinkla, Kaski, & Dumitriu, 2016) . Animal studies have shown that Treg therapies are an intriguing strategy for CVD treatment; however, without translational studies this therapy is severely lacking.
Vaccination
Vaccination therapies have also gained attention for expanding atheroprotective immune functions. Lipids, especially LDL and its modified counterparts, contribute significantly to the progression of atherosclerosis; therefore, several studies have investigated and reported the inhibitory effects of LDL immunization on plaque development (Ameli et al., 1996; Chyu et al., 2004) . However, recent research has begun to investigate specific atheroprotective epitopes of lipoproteins because whole molecules of LDL are too impractical for clinical vaccines considering their size and complexity (Chyu, Dimayuga, & Shah, 2017) . In particular, epitopes from apolipoprotein B100 (ApoB100), the protein component of LDL, have emerged as prime therapeutic candidates. Several studies have reported reductions in atherosclerosis, including reduced plaque size as well as macrophage content, after vaccination with T-cell ApoB100 epitopes (Gisterå et al., 2017; Kimura et al., 2017) . Further immunization experiments with ApoB100 peptide 18 resulted in an enriched Treg phenotype as well as reductions in lesion size (Kimura et al., 2018) . While these therapies are advantageous in the fact that they leave host defense mechanisms untouched, induction of immune responses through self-antigens could have severe consequences. Currently, the V6 vaccine, containing various pooled adipose tissue antigens, is under evaluation in a clinical trial aiming to reduce atherosclerosis in overweight and obese patients (Bourinbaiar & Jirathitikal, 2010) . Overall, anti-inflammatory and immune modulating therapies are a very promising strategy for cardiovascular treatment. Targeting specific immune cells, either atherogenic or atheroprotective, to balance our immune response during chronic inflammation seems reasonable. While the effects of atherosclerosis are initiated by lipids, these therapies may be targeting our immune system rather than the interaction between immune cells and lipids to resolve this problem. New strategies are being developed which target the cellular, or primarily epigenetic, effects of lipids and dyslipidemia on immune cells.
Epigenetic therapies
The emerging field of epigenetics has become increasingly prevalent in the search for potential therapeutics for atherosclerosis as our understanding of regulators of immune cell function and differentiation improves. Epigenetics can be defined as any heritable change not associated with alterations in DNA sequence. Although the most well studied epigenetic modulation remains DNA methylation, additional modulations such as histone post-translational modifications and noncoding RNA have also been shown to be associated with disease conditions like atherosclerosis (Feinberg & Moore, 2016; Greißel et al., 2015) . These modifications serve to disseminate cellular memory; however, one key feature of epigenetic modifications is their dynamic nature. Depending on environmental stimuli, these modifications have the ability to alter gene expression as well as cell phenotype by allowing chromosomal regions to change their accessibility to transcription factors (Khyzha, Alizada, Wilson, & Fish, 2017) . Known risk factors for CVD, such as diet and smoking, may alter environmental stimuli that immune cells interact with thus influencing both epigenetic modifications and further cell differentiation. Within those cells, particular genes may be effectively turned on or off depending on its chromosomal accessibility leading to alterations in downstream gene products and cell phenotypes. As described above, this phenotype switching and priming of both innate and adaptive immune cells in the presence of atherogenic stimuli, such as oxLDL, could help explain the strong inflammatory response seen in the arterial wall during atherosclerosis (Hoogeveen et al., 2017) .
Chromatin-modifying enzymes
Many epigenetic processes are tightly regulated by writer and eraser complexes, which have the ability to propagate or silence certain pathways. As discussed previously, histone methyltransferases as well as demethylases, e.g. EZH2 and JMJD3, play important and opposing roles in epigenetic modulations. Considering this fact, chromatin-modifying enzymes have become an interesting therapeutic target in many disease states (Coit et al., 2016; Tong et al., 2014) . Although drug development for inhibitors of modulators such as histone deacetylases (HDACs) and DNA methyltransferases (DNMTs) has rapidly expanded, research in atherosclerosis is still poor (Hoogeveen et al., 2017) . One prime target for epigenetic modulation is HDAC3, which is upregulated in human plaques. A pro-fibrotic plaque phenotype was observed in mice deficient in myeloid HDAC3, which researchers linked to regulation of the Tgfb1 loci. Murine macrophages were skewed to an anti-inflammatory phenotype with a reduction in foam cells found in plaques (Hoeksema et al., 2014) . Similarly, HDAC9 has also been associated with increases in atherosclerotic lesion sizes in Apoe −/− mice suggesting it may be an attractive therapeutic target as well (Azghandi et al., 2015) . Additional research studying the relationship between lipids and immune cells may uncover more epigenetic enzymes that directly affect plaque progression and stability.
Methylation patterns
Interestingly, several genome wide methylation studies have discovered atherosclerosis-specific methylation patterns (Aavik et al., 2015; Z. Wang & Patel, 2014; Zaina et al., 2014) . While these studies have provided the basis for exploring epigenetic targets in atherosclerosis, their results have been inconsistent when reporting the level of methylation in human plaques. Further studies have suggested differences in methylation patterns between early and late stage human plaques, which may help explain the discrepancies seen in earlier studies (Greißel et al., 2015) . Under hyperlipidemic conditions, several studies have found changes in the methylation pattern of trimethylation of lysine 4 at histone 3 in both monocytes and T cells, which may represent a key to their epigenetic remodeling (Bekkering et al., 2014; Tie, Yan, Khair, Messina, & Deng, 2017) . Although a definitive methylation pattern in atherosclerotic plaques remains elusive, future studies focusing on both stage and cell-specific epigenetic signatures might lead to targeted anti-inflammatory therapies.
Conclusion
In this review, we outlined the current knowledge surrounding the cross talk between lipids and immune cells, particularly in cases of dyslipidemia. Throughout the decades of cardiovascular research, it has become abundantly clear that lipids and immune cells cooperatively drive atherosclerosis. Surprisingly, though, current treatment recommendations take a one-sided approach to CVD through lipid-lowering therapeutics leaving a large residual risk. However in light of the success of the CANTOS trial, anti-inflammation therapies targeting specific aspects of the immune system may be poised to address this additional need. Although we have described what is currently known about these issues, the mechanisms driving both anti-and pro-atherogenic changes during lipid-immune cell interactions still need to be clarified. As our understanding of immune cell phenotypic switching and epigenetic signatures improves, this knowledge can be applied to multiple chronic inflammatory conditions including atherosclerosis. A combination therapy involving both lipid-lowering and anti-inflammatory treatments may be the first step towards personalized medicine for patients suffering from cardiovascular disease. • Antigen processing and presentation • Cytokine production to assist with immune response Subsets:
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• First responder to antigenic material through phagocytosis • Extracellular traps using DNA to activate innate immune signaling
LDL Modifications Aggregation
• Interaction with proteoglycans, especially in the sub-endothelial layer of the vessel intima, may destabilize apoB conformation causing aggregation and increase foam cell formation. Lipolysis
• Various enzymes, including phospholipase A and sphingomyelinase, may be found in the sub-endothelial layer of the vessel intima, which can modify deposited LDL. These enzymes may hydrolyze LDL lipoproteins allowing for additional aggregation, as well as fusion of LDL particles in the case of sphingomyelinase, in the presence of proteoglycans ultimately increasing foam cell formation. Oxidation
• Endothelial cells may induce oxidative changes to LDL through free radical modifications producing a wide range of antigenic epitopes in both its lipid and protein portions.
Progenitor and Stem Cells CXCR4/CXCL12 axis • Chemokines, like CXCL12, are small chemoattractant molecules. Although expressed ubiquitously, it forms a homing system through its cognate receptor, CXCR4, in the bone marrow. Typically, decreases in the expression of CXCL12 allow for increased bone mobilization. Hematopoietic Progenitor and Stem Cells
• Progenitor cells for all cells involved in the immune system through hematopoiesis. HSPCs are found in the bone marrow of most large bones of adults and ultimately migrate to outside locations for further differentiation.
